Annual report pursuant to Section 13 and 15(d)

Acquisition of Pelican Therapeutics (Narrative) (Details)

v3.19.1
Acquisition of Pelican Therapeutics (Narrative) (Details) - USD ($)
1 Months Ended 12 Months Ended
May 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Business Acquisition [Line Items]        
Issuance of common stock Pelican, shares   133,106  
Accrued liabilities   $ 1,678,051 $ 2,276,431  
Goodwill   2,189,338 2,189,338
In-process R&D   5,866,000 5,866,000  
Revenue   5,793,849 1,519,943  
Net loss (income)   $ (15,733,854) $ (11,841,671)  
Pelican Therapeutics, Inc. [Member]        
Business Acquisition [Line Items]        
Percentage of voting interests acquired in acquisition   85.00% 80.00%  
Issuance of common stock Pelican, shares   133,106    
Percentage of outstanding common shares issued for equity consideration in business acquisition   4.99%    
Percentage of probability-weighted   7.20%    
Cash consideration   $ 500,000    
Accrued liabilities   200,000    
Fair value of contingent consideration   500,000 $ 200,000  
Goodwill   2,189,338    
In-process R&D   $ 5,900,000    
Percentage of non-controlling interest acquired   20.00%    
Revenue   $ 150,000    
Amount awarded from CPRIT grant $ 15,200,000 7,600,000    
Total matching funds provided by Company   5,200,000    
Remaing matching funds to be provided by Company   3,500,000    
Remaining matching funds to be provided by Company for third fiscal year   7,600,000    
Total grant funds provided by CPRIT   8,300,000    
Remaining grant funds to be provided by CPRIT   $ 6,900,000    
Pelican Therapeutics, Inc. [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Percentage of non-controlling interest acquired   10.00%    
Pelican Therapeutics, Inc. [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Percentage of non-controlling interest acquired   15.00%    
Pelican Therapeutics, Inc. [Member] | Stockholders [Member]        
Business Acquisition [Line Items]        
Cash consideration   $ 300,000